Trial Profile
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children With Previously Untreated Patients With Aggressive Non-Hodgkin's Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Filgrastim; Prednisone; Vincristine
- Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 31 Oct 2020 Planned End Date changed from 31 Mar 2023 to 30 Jun 2025.
- 31 Oct 2020 Planned End Date changed from 31 Mar 2023 to 30 Jun 2025.
- 31 Oct 2020 Planned primary completion date changed from 31 Mar 2021 to 30 Jun 2025.